

Trial premature ended

The study GDP-01-01 was prematurely terminated on 03MAY2017, at Sponsor's decision, after an interim analysis.

This interim analysis showed no evidence of efficacy, i.e. did not prove the concept that CPD genotyping is able to distinguish between responders and non-responders to perindopril, among a population of obese subjects.